List of proprietary Chinese medicines that have passed the formal review of the national medical insurance catalogue in 2022

The 250 billion yuan Chinese patent medicine hospital market is booming again! Recently, the 2022 National Medical Insurance Catalogue was released through the formal review list, and 50 proprietary Chinese medicines were listed, and there were 35 and 15 inside and outside the
list.
Among the 50 proprietary Chinese medicines, there are 45 modern dosage forms, and Chinese medicine injections account for 4; In addition to the procardinone drop pills, 49 proprietary Chinese medicines belong to exclusive varieties
.

2022 medical insurance catalogue adjustment review of proprietary Chinese medicines outside the catalogue

There are two kinds of drug declaration conditions in the 2022 medical insurance adjustment catalogue, and condition 1 is the negotiated drug whose agreement expires on December 31, 2022, and the validity period of the agreement includes the validity period of the negotiation agreement and the validity period of the renewal agreement; Condition 2 is the negotiated drugs and other drugs in the list that have undergone major changes in indications or functional indications between 2017 and June 30, 2022 with the approval of the national drug regulatory authorities (including the application for adjustment of the scope of medical insurance payment for renewal drugs in 2022).

Of the 35 proprietary Chinese medicines in the catalogue that passed the formal review, 31 varieties were selected through the catalogue condition 1, and the other 4 varieties were selected through the catalog condition 2, including Shenwei Pharmaceutical's lipid-lowering Tongluo soft capsules, Convert's Pharmaceutical's Converter injection, China-US East China's Bailing capsules, Shaanxi Jianmin Pharmaceutical's Leech Snake Tongluo Capsules, etc
.

2022 Medical Insurance Catalogue Adjustment Review Catalogue of Chinese Proprietary Medicine

The medical insurance directory access negotiations have been carried out four times since the establishment of the National Medical Insurance Bureau, and from the perspective of the 50 proprietary Chinese medicines that have passed the formal examination, the number of proprietary Chinese medicines outside the list has increased by 87.
5% compared with 2021, and the number of proprietary Chinese medicines in the directory has increased by 52.
2% compared with 2021, and the pace of proprietary Chinese medicines entering medical insurance has further accelerated
.

It is worth noting that the preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug catalogue and the integrity of drug information in that year.

According to the Interim Measures for the Administration of Drugs in Basic Medical Insurance and the Work Plan for the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance in 2022, the adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding, etc.
, and formal review is only one of
them.

Through the formal review, it is indicated that the drug is eligible for the next step of the expert review process
.
Only by successfully passing all the links of the catalogue adjustment can it be finally included in the national medical insurance drug list
.
Exclusive drugs that pass the review are negotiated, non-exclusive drugs are bidd, and only successful negotiations or bids can be included in the list
.
What is the ultimate fate of the 50 proprietary Chinese medicines, we will continue to pay attention to
.